Screening of FDA-Approved Drugs Using a MERS-CoV Clinical Isolate from South Korea Identifies Potential Therapeutic Options for COVID-19
dc.contributor.author | Meehyun, Ko | |
dc.contributor.author | Chang, Soo Young | |
dc.contributor.author | Byun, Soo Young | |
dc.contributor.author | Ianevski, Aleksandr | |
dc.contributor.author | Choi, Inhee | |
dc.contributor.author | Pham Hung, Anne-Laure | |
dc.contributor.author | Ravlo, Erlend | |
dc.contributor.author | Wang, Wei | |
dc.contributor.author | Bjørås, Magnar | |
dc.contributor.author | Kainov, Denis | |
dc.contributor.author | Shum, David | |
dc.contributor.author | Min, Ji-Young | |
dc.contributor.author | Windisch, Marc P. | |
dc.date.accessioned | 2023-01-23T09:02:42Z | |
dc.date.available | 2023-01-23T09:02:42Z | |
dc.date.created | 2022-01-11T12:53:26Z | |
dc.date.issued | 2021 | |
dc.identifier.issn | 1999-4915 | |
dc.identifier.uri | https://hdl.handle.net/11250/3045156 | |
dc.description.abstract | Therapeutic options for coronaviruses remain limited. To address this unmet medical need, we screened 5406 compounds, including United States Food and Drug Administration (FDA)-approved drugs and bioactives, for activity against a South Korean Middle East respiratory syndrome coronavirus (MERS-CoV) clinical isolate. Among 221 identified hits, 54 had therapeutic indexes (TI) greater than 6, representing effective drugs. The time-of-addition studies with selected drugs demonstrated eight and four FDA-approved drugs which acted on the early and late stages of the viral life cycle, respectively. Confirmed hits included several cardiotonic agents (TI > 100), atovaquone, an anti-malarial (TI > 34), and ciclesonide, an inhalable corticosteroid (TI > 6). Furthermore, utilizing the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), we tested combinations of remdesivir with selected drugs in Vero-E6 and Calu-3 cells, in lung organoids, and identified ciclesonide, nelfinavir, and camostat to be at least additive in vitro. Our results identify potential therapeutic options for MERS-CoV infections, and provide a basis to treat coronavirus disease 2019 (COVID-19) and other coronavirus-related illnesses. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | MDPI | en_US |
dc.rights | Navngivelse 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/deed.no | * |
dc.title | Screening of FDA-Approved Drugs Using a MERS-CoV Clinical Isolate from South Korea Identifies Potential Therapeutic Options for COVID-19 | en_US |
dc.title.alternative | Screening of FDA-Approved Drugs Using a MERS-CoV Clinical Isolate from South Korea Identifies Potential Therapeutic Options for COVID-19 | en_US |
dc.type | Peer reviewed | en_US |
dc.type | Journal article | en_US |
dc.description.version | publishedVersion | en_US |
dc.source.volume | 13 | en_US |
dc.source.journal | Viruses | en_US |
dc.source.issue | 4 | en_US |
dc.identifier.doi | 10.3390/v13040651 | |
dc.identifier.cristin | 1978301 | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 |